Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: A meta-analysis of randomized controlled trials
- 1 September 2019
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 141, 163-173
Abstract
No abstract availableKeywords
Funding Information
- BP – A Beneficencia Portuguesa de Sao Paulo
This publication has 34 references indexed in Scilit:
- Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: An up-to-date review and meta-analysis of clinical trialsInternational Journal of Cancer, 2014
- Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian CancerJournal of Clinical Oncology, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cellsProceedings of the National Academy of Sciences, 2011
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA StatementJournal of Clinical Epidemiology, 2009
- Mechanisms of Cancer-Related FatigueThe Oncologist, 2007
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005
- Measuring inconsistency in meta-analysesBMJ, 2003
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986